AACR Announces Recipients of AACR Trailblazer Cancer Research Grants
AACR’s largest-ever grant program will award 15 early-stage and mid-career investigators with $1 million each over 3 years SAN...
AACR’s largest-ever grant program will award 15 early-stage and mid-career investigators with $1 million each over 3 years SAN...
The investigational drug led to objective response and disease control in patients with late-stage disease SAN DIEGO – Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced...
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose...
SAN DIEGO – The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC)...
SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which...
PHILADELPHIA – The American Association for Cancer Research (AACR) is pleased to announce the recipients of the 2026 AACR...
SAN DIEGO – The American Association for Cancer Research (AACR) will honor leaders from government and the advocacy community...
SAN DIEGO – The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during...
SAN DIEGO – The American Association for Cancer Research (AACR)-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer...
SAN DIEGO – The American Association for Cancer Research (AACR) will present the 2026 AACR Award for Lifetime Achievement...